Board of Directors
Co-Founder & Chairman of Board
In addition to his role with Aelan, Chester is also the chairman and CEO of US Equity Holdings. Chester has more than twenty years of experience in founding, operating and financing businesses, from startups to multimillion-dollar publicly traded companies. +/-
He has assembled world-class teams and helped raise more than $150 million of private equity for long-term financing of numerous ventures in the fields of entertainment, clean energy (solar and biofuels), Internet and publishing, among others.
Chester has also worked closely with his partners on licensing major Hollywood properties such as Frank Miller's Sin City and numerous Disney brands. He was responsible for securing sales and distribution rights worth tens of millions of dollars from partners including Sony, Atari and Vivendi Universal. His most recent projects are focused on biotechnology and biomedicine.
By working with scientists from research institutes and universities around the globe (NASA, the Buck Institute, Stanford and Fraunhofer), Chester is particularly experienced in understanding innovation-focused culture. This knowledge helps him provide the business and financial infrastructure for early-stage development of innovative products, treatments and technologies.
Dr. Lunyak’s areas of expertise include epigenetics, genomics and stem cell research. She has a distinguished track record of research discoveries and innovations, as a grant recipient from the International Soros Foundation to her stellar accomplishments in academia. +/-
Dr. Lunyak carried out her research in world-leading institutions, including Brown University, the University of California, San Diego, and most recently, at the Buck Institute for Research on Aging.
Her research discoveries have been published in Science, Cell, Genes and Development and other journals, with more than 5,000 scientific citations and coverage in media across the globe. Many of her scientific innovations are patented and licensed worldwide.
Dr. Lunyak has presented hundreds of lectures and seminars at leading universities as well as at national and international scientific meetings. She has served on numerous journal editorial boards as well as study sections, panels and committees for the National Institutes of Health, the National Science Foundation, the Wellcome Trust and many other national and international agencies.
Dr. Lunyak received her Master of Science degree in Biophysics from St. Petersburg Polytechnic University in St. Petersburg, Russia, and earned her PhD in Molecular Biology from the Petersburg Nuclear Physics Institute at the Russian Academy of Science.
Winnie Wan, PhD
Winnie Wan, PhD is an industry veteran, with extensive experience in launching and building diagnostic and therapeutic businesses with start-ups and within large corporations in the last 30 years. She has successfully commercialized disruptive technologies from inception. +/-
These technologies include the analytical systems for drug development at ForteBio, Inc. (acquired by Pall Corporation), the anatomical pathology systems for cancer diagnosis at Becton Dickinson, the cell analysis systems at Guava Technologies, Inc. (acquired by Millipore Corporation), and the HIV drug model at SyStemix, Inc.(acquired by Novartis). Dr. Wan is currently the Executive Chairman and founding CEO of OncoHealth Corp., a company dedicated to commercialize novel proprietary diagnostic/screening tests for cancers associated with human Papilloma virus (HPV). She also serves on the Board of Nanotech BioMachines. Inc.
Previously, Dr. Wan held CEO/Board or Executive positions at BEING Biopharma, Inc., ForteBio, Inc., GeneTrol BioTherapeutics, Inc.; Guava Technologies, Inc.; Becton Dickinson’s CIS Division, SyStemix, Inc. etc.. She received her B.A. from Skidmore College; Ph.D. in Biochemistry from Yale University, post-doctoral training in cell biology at Rockefeller University and M.B.A. from Columbia University.